252 related articles for article (PubMed ID: 28524152)
1. [Vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration].
Dyakov IN; Zyryanov SK
Vestn Oftalmol; 2017; 133(2):125-129. PubMed ID: 28524152
[TBL] [Abstract][Full Text] [Related]
2. VEGF inhibitors for the treatment of neovascular age-related macular degeneration.
Barakat MR; Kaiser PK
Expert Opin Investig Drugs; 2009 May; 18(5):637-46. PubMed ID: 19388880
[TBL] [Abstract][Full Text] [Related]
3. Current status of vascular endothelial growth factor inhibition in age-related macular degeneration.
Mousa SA; Mousa SS
BioDrugs; 2010 Jun; 24(3):183-94. PubMed ID: 20210371
[TBL] [Abstract][Full Text] [Related]
4. Promising new treatments for neovascular age-related macular degeneration.
Michels S; Schmidt-Erfurth U; Rosenfeld PJ
Expert Opin Investig Drugs; 2006 Jul; 15(7):779-93. PubMed ID: 16787141
[TBL] [Abstract][Full Text] [Related]
5. Anti-VEGF agents for age-related macular degeneration.
Ozkiris A
Expert Opin Ther Pat; 2010 Jan; 20(1):103-18. PubMed ID: 20021287
[TBL] [Abstract][Full Text] [Related]
6. Current therapeutic approaches in neovascular age-related macular degeneration.
Nguyen DH; Luo J; Zhang K; Zhang M
Discov Med; 2013 Jun; 15(85):343-8. PubMed ID: 23819948
[TBL] [Abstract][Full Text] [Related]
7. Anti-vascular endothelial growth factor therapy for ocular neovascular disease.
Andreoli CM; Miller JW
Curr Opin Ophthalmol; 2007 Nov; 18(6):502-8. PubMed ID: 18163003
[TBL] [Abstract][Full Text] [Related]
8. [Role of genetic markers in personalization of anti-angiogenic therapy in patients with exudative age-related macular degeneration].
Moshetova LK; Sychev DA; Osmanova ER; Turkina KI
Vestn Oftalmol; 2017; 133(6):120-125. PubMed ID: 29319678
[TBL] [Abstract][Full Text] [Related]
9. Profile of conbercept in the treatment of neovascular age-related macular degeneration.
Lu X; Sun X
Drug Des Devel Ther; 2015; 9():2311-20. PubMed ID: 25960634
[TBL] [Abstract][Full Text] [Related]
10. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.
Ng EW; Adamis AP
Can J Ophthalmol; 2005 Jun; 40(3):352-68. PubMed ID: 15947805
[TBL] [Abstract][Full Text] [Related]
11. [Anti-VEGF therapy resistance in neovascular age-related macular degeneration].
Budzinskaya MV; Plyukhova AA; Sorokin PA
Vestn Oftalmol; 2017; 133(4):103-108. PubMed ID: 28980574
[TBL] [Abstract][Full Text] [Related]
12. Emerging therapies for the treatment of wet age-related macular degeneration--VEGF Trap-Eye.
Rejdak R; Szkaradek M; Grieb P; Jünemann AG
Klin Oczna; 2011; 113(10-12):376-8. PubMed ID: 22384659
[TBL] [Abstract][Full Text] [Related]
13. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):158-65. PubMed ID: 19417570
[TBL] [Abstract][Full Text] [Related]
14. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review.
Yang S; Zhao J; Sun X
Drug Des Devel Ther; 2016; 10():1857-67. PubMed ID: 27330279
[TBL] [Abstract][Full Text] [Related]
15. Association of neovascular age-related macular degeneration with month and season of birth in Italy.
Longo A; Casuccio A; Pani L; Avitabile T; Cillino S; Uva MG; Bonfiglio V; Russo A; Parisi G; Cennamo G; Furino C; Parravano M; Xoxi E; Reibaldi M
Aging (Albany NY); 2016 Dec; 9(1):133-141. PubMed ID: 27997361
[TBL] [Abstract][Full Text] [Related]
16. Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration.
Nguyen TT; Guymer R
Expert Rev Clin Pharmacol; 2015; 8(5):541-8. PubMed ID: 26289225
[TBL] [Abstract][Full Text] [Related]
17. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration.
Dixon JA; Oliver SC; Olson JL; Mandava N
Expert Opin Investig Drugs; 2009 Oct; 18(10):1573-80. PubMed ID: 19694600
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis].
Michels S; Rosenfeld PJ
Klin Monbl Augenheilkd; 2005 Jun; 222(6):480-4. PubMed ID: 15973626
[TBL] [Abstract][Full Text] [Related]
19. Antibody therapies and their challenges in the treatment of age-related macular degeneration.
Volz C; Pauly D
Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):158-72. PubMed ID: 25725263
[TBL] [Abstract][Full Text] [Related]
20. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
Ferrara N; Damico L; Shams N; Lowman H; Kim R
Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
